Joel Ang, MD
Family Medicine · Washington, DCNPI 1992792568
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Gilead at 50.9% of the total. Reporting peaked in 2019 at $9,348 and has fallen 98.0% since, to $183 in 2025. Among family medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $46.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Theratechnologies Inc.$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Viiv Healthcare Company$865
- Medicure Pharma Inc.$600
- AstraZeneca$347
- plus $2K from 20 others
What the payments were for
- Consulting fees$5,85042%
- Speaking & faculty fees$1,1799%
- Travel & lodging$1,50211%
- Food & beverage$5,12237%
- Education$1141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 99 | $7,004 |
| Theratechnologies Inc. | 15 | $1,514 |
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| Viiv Healthcare Company | 40 | $865 |
| Medicure Pharma Inc. | 2 | $600 |
| AstraZeneca | 18 | $347 |
| Johnson & Johnson(2 entities) | 14 | $322 |
| Novo Nordisk | 15 | $242 |
| Amgen | 14 | $239 |
| Merck | 18 | $218 |
| Pfizer | 7 | $119 |
| Sanofi | 1 | $110 |
| AbbVie | 8 | $106 |
| Amarin Pharma, Inc. | 6 | $102 |
| Lilly USA, LLC | 5 | $101 |
| Janssen Products, LP | 1 | $100 |
| Boehringer Ingelheim | 4 | $100 |
| Antares Pharma, Inc. | 5 | $96 |
| Mylan Institutional Inc. | 4 | $96 |
| Napo Pharmaceuticals Inc | 4 | $71 |
| Mylan Pharmaceuticals Inc. | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Aytu Biopharma, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$4,549
- NURTEC ODT$1,200
- TROGARZO$903
- Descovy$860
- HMG-CoA reductase inhibitor.$600
- DOVATO$122
- TOUJEO$110
How this compares
$13,768 in reported general payments places this provider in the 95th percentile of 166 family medicine providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 25 | $95,792 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $54,504 |
| PrezcobixDarunavir/Cobicistat | 15 | $50,605 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $35,791 |
| OzempicSemaglutide | 19 | $31,902 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $30,768 |
| EliquisApixaban | 14 | $9,518 |
| VascepaIcosapent Ethyl | 12 | $7,040 |
| Testosterone | 17 | $5,529 |
| Rosuvastatin Calcium | 84 | $1,796 |
| Metoprolol Succinate | 31 | $512 |
| Omeprazole | 18 | $466 |
| Levothyroxine Sodium | 29 | $457 |
| Acyclovir | 12 | $380 |
| Atorvastatin Calcium | 41 | $369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Dovato | $865 | $85,27222 claims |
| Johnson & JohnsonPrezcobix | $322 | $50,60515 claims |
| GileadDescovy | $7,004 | $35,79114 claims |
| Novo NordiskOzempic | $242 | $31,90219 claims |
| PfizerEliquis, Paxlovid | $119 | $9,51828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 family medicine providers in District of Columbia.
Other family medicine in Washington
- Mark JohnsonWashington$38K
- Charles GreenWashington$25K
- Barry ClarkWashington$17K
- Kandie TateWashington$12K
- Ghulam AbbasWashington$9K
- Megha MendirattaWashington$6K
- Minerva CamposWashington$5K
- Kathleen UhlWashington$5K
- Mikel HofmannWashington$4K
- Kyle BendaWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.